查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2022-按产品类型（速效胰岛素、长效胰岛素、复合胰岛素、生物仿製药）、应用、类型（1 型、2 型）、分销渠道、地区分部预测的胰岛素市场规模、份额和趋势分析2030
市场调查报告书
商品编码
1114020

2022-按产品类型（速效胰岛素、长效胰岛素、复合胰岛素、生物仿製药）、应用、类型（1 型、2 型）、分销渠道、地区分部预测的胰岛素市场规模、份额和趋势分析2030

Insulin Market Size, Share & Trends Analysis By Product Type (Rapid-Acting Insulin, Long-Acting Insulin, Combination Insulin, Biosimilar), By Application, By Type (Type 1, Type 2), By Distribution Channel, By Region, & Segment Forecasts, 2022 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

胰岛素市场增长和趋势

根据 Grand View Research, Inc. 的一份新报告，到 2030 年，全球胰岛素市场预计将达到 232 亿美元，在预测期内以 1.5% 的复合年增长率增长。

市场已成为由 Novo Nordisk A/S、Sanofi、Eli Lilly 和 Company 等公司主导的寡头垄断空间。糖尿病发病率的上升和胰岛素给药製剂的进步是增长的主要驱动力。然而，用于治疗 2 型糖尿病的生物仿製药和 GLP-1 RA 等药物的存在可能会在一定程度上减缓市场增长。

糖尿病是世界上增长最快的慢性病之一。在过去的几十年里，它的流行率稳步上升。这种疾病的流行在低收入和中等收入国家迅速增加，其中四分之三的成年人患有糖尿病。根据国际糖尿病联盟（IDF）的 2021 年数据，到 2030 年将有大约 6.43 亿人患有糖尿病，到 2045 年将有 7.83 亿人患有糖尿病。此外，人口老龄化和肥胖人口的增加也是促进增长的因素。超重人群有患 2 型糖尿病的风险。根据世界卫生组织的数据，到 2020 年将有 19 亿成年人超重，占该年龄组人口的 39%。

胰岛素输送系统的配方进展正在开发中，预计它们的推出将在预测期内推动市场。 2019 年 12 月，来自 Tandem Diabetes Care 的可互操作设备 Control-IQ 在美国获得 FDA 营销批准，作为一种可与其他可互操作设备一起使用的自动胰岛素给药算法。

由三大製造商主导：礼来公司、诺和诺德 A/S 和赛诺菲。这些公司占据了90%以上的市场份额。由于市场寡头垄断和专利保护，胰岛素的成本很高。因此，产品的高成本会阻碍行业发展。

COVID-19 大流行对该行业产生了不利影响。患有糖尿病等慢性疾病的人对紧急和常规医疗护理造成了相当大的干扰。根据 NCBI 的一篇文章，在美国大约 3000 万糖尿病患者中，大约有 750 万依赖胰岛素。胰岛素配给和囤积已经是一个普遍存在的问题，并且在大流行期间由于供应问题而增加。然而，在一些国家，COVID-19 的影响在 2020 年第三季度之后减弱，恢復了市场吸引力。

胰岛素市场报告亮点

长效胰岛素部门在 2021 年获得了 56.53% 的可观收入份额。由于专利保护和长期影响导致的高需求等因素预计将推动该细分市场

由于这些患者对胰岛素的高度依赖，2021 年 1 型糖尿病将占应用领域的最大份额

胰岛素类似物细分市场将在 2021 年占据主导地位。这是因为与常规治疗相比，胰岛素更有效，副作用更少，如低血糖和体重增加更少

由于零售药店连锁店的存在以及这些连锁店隶属于医院这一事实，2021 年的分销渠道将由零售药店部分主导

北美在 2021 年的销售中占据市场主导地位，主要是由于该地区的品牌优势和糖尿病患病率上升

内容

第1章调查方法及范围

  • 市场细分
    • 估计/预测时间表
  • 调查方法
  • 信息采购
    • 购买的数据库
    • GVR 内部数据库
    • 辅助信息
    • 初步调查
    • 初步调查的内容
    • 主要信息列表
  • 信息或数据分析
    • 数据分析模型
  • 市场製定和验证
  • 型号详情
    • 商品流向分析
      • 方法 1：商品流通方法
      • 方法 2：使用自下而上的方法估算国别市场
  • 全球市场：CAGR 计算
  • 调查假设
  • 辅助信息列表
  • 缩写列表
  • 目的

第 2 章执行摘要

  • 市场概览

第 3 章市场变量、趋势和范围

  • 市场系列展望
    • 母公司市场展望
  • 监管框架
  • 绘製渗透率和增长前景
  • 管道分析
  • 市场动态
    • 市场驱动因素分析
      • 糖尿病患病率不断上升
      • 不断增长的老年人和肥胖人口
      • 胰岛素输送系统的配方进展
    • 市场约束分析
      • 胰岛素成本高
      • 退款政策不佳
      • 推出胰岛素生物仿製药和扩大 glp-1 激动剂
  • 波特五力分析
  • PESTEL 分析
  • COVID-19 的影响

第 4 章全球胰岛素市场 - 细分分析，产品类型，2018-2030 年（百万美元）

  • 世界胰岛素市场：产品类型的变化分析
  • 速效胰岛素
  • 长效胰岛素
  • 同时使用胰岛素
  • 生物仿製药
  • 其他

第 5 章全球胰岛素市场 - 细分分析，按类型，2018-2030 年（百万美元）

  • 世界胰岛素市场：类型变化分析
  • 人胰岛素
  • 胰岛素类似物

第 6 章全球胰岛素市场 - 2018-2030 年细分分析、应用（百万美元）

  • 世界胰岛素市场：应用变化分析
  • 1 型糖尿病
  • 2 型糖尿病

第 7 章全球胰岛素市场 - 细分分析，按分销渠道，2018-2030 年（百万美元）

  • 全球胰岛素市场：分销渠道变化分析
  • 医院药房
  • 零售药房
  • 其他

第 8 章胰岛素市场：细分分析，按地区，2018-2030 年（百万美元）

  • 胰岛素市场：区域差异分析
    • 北美
      • 美国
      • 加拿大
    • 欧洲
      • 英国
      • 德国
      • 法国
      • 西班牙
      • 意大利
    • 亚太地区
      • 日本
      • 中国
      • 印度
      • 澳大利亚
      • 韩国
    • 拉丁美洲
      • 巴西
      • 墨西哥
      • 阿根廷
    • 中东和非洲
      • 南非
      • 沙特阿拉伯
      • 阿拉伯联合酋长国

第 9 章全球胰岛素市场：竞争分析

  • 主要市场参与者的近期趋势和影响分析
    • 协同效应分析：主要交易和战略联盟
      • 推出新产品
      • 併购
      • 合作伙伴关係和合同
  • 公司分类
    • 创新者
    • 市场领导者
    • 新兴玩家
    • 热图分析
  • 公司市场分析
  • 供应商情况
    • 主要分销商和渠道合作伙伴列表
    • 潜在最终用户列表
    • 2021 年主要参与者的市场份额分析
  • 2021 年公司市场份额/排名
    • 市场份额/公司排名，速效胰岛素，2021 年
    • 市场份额/公司排名，长效胰岛素，2021 年
    • 公司市场份额/排名，生物仿製药，2021 年
    • 公司市场份额/排名，其他，2021 年
    • 竞争信息中心分析
  • 私人公司
    • 主要初创公司列表
    • 本地网络地图
  • 公司简介
    • 礼来公司
      • 公司简介
      • 财务表现
      • 产品基准
      • 战略举措
    • 赛诺菲
      • 公司简介
      • 财务表现
      • 产品基准
      • 战略举措
    • 诺和诺德 A/S
      • 公司简介
      • 财务表现
      • 产品基准
      • 战略举措
    • Biocon
      • 公司简介
      • 财务表现
      • 产品基准
      • 战略举措
    • 勃林格殷格翰国际有限公司
      • 公司简介
      • 财务表现
      • 产品基准
      • 战略举措
    • 通化东宝药业有限公司
      • 公司简介
      • 产品基准
      • 战略举措
    • 沃克哈特
      • 公司简介
      • 财务表现
      • 产品基准
    • 朱尔法
      • 公司简介
      • 财务表现
      • 产品基准
      • 战略举措
    • 联合实验室国际控股有限公司
      • 公司简介
      • 财务表现
      • 产品基准
Product Code: GVR-4-68039-951-3

Insulin Market Growth & Trends:

The global insulin market is expected to reach USD 23.20 billion by 2030, expanding at a CAGR of 1.5% during the forecast period, according to a new report by Grand View Research, Inc. It is an oligopolistic space dominated by companies such as Novo Nordisk A/S, Sanofi, and Eli Lilly and Company. The increasing incidence of diabetes and formulation advancements in insulin delivery are the primary factors driving growth. However, the presence of biosimilars and drugs such as GLP-1 RAs for the treatment of type 2 diabetes can slow down market growth to a certain extent.

Diabetes is one of the fastest-growing chronic diseases in the world. Its prevalence has increased steadily over the past few decades. The prevalence of the disease is growing rapidly in low- and middle-income countries; three in four adults live with diabetes in these countries. According to the International Diabetes Federation (IDF) data from 2021, approximately 643 million individuals will have diabetes by 2030 and 783 million by 2045. In addition, the increase in geriatric and obese populations is another factor driving growth. The overweight population is at risk of developing type 2 diabetes mellitus. According to WHO, in 2020, 1.9 billion adults were found to be overweight, accounting for 39% of the population within that age group.

Formulation advancements in insulin delivery systems are being developed, the release of which is likely to propel the market over the forecast period. In December 2019, Tandem Diabetes Care's Control-IQ, an interoperable device, received FDA authorization for marketing in the U.S. It is an automated insulin dosing algorithm that can be used with other interoperable devices.

The top three manufacturing companies, Eli Lilly and Company, Novo Nordisk A/S, and Sanofi, hold a monopoly. These companies hold more than 90% of the market share. Owing to the oligopolistic nature of the market and patent protection, the cost of insulin is high. Hence, the high cost of products could impede industry growth.

The COVID-19 pandemic caused a detrimental impact on the industry. Individuals with chronic illnesses, such as diabetes, have experienced substantial disruptions in emergency and routine medical care. According to an NCBI article, out of ~30 million diabetic patients in America, about 7.5 million are dependent on insulin. Insulin rationing or hoarding has already been a rampant issue, which increased further amid the pandemic due to supply concerns. However, in several countries, the effect of COVID-19 declined to post the third quarter of 2020, which helped the market regain traction.

Insulin Market Report Highlights:

  • The long-acting insulin segment contributed a significant revenue share of 56.53% in 2021. Factors such as patent protection and high demand due to long-term effects are expected to drive the segment
  • Type 1 diabetes mellitus is the largest segment by application in 2021 due to the high insulin dependency of these patients
  • Insulin analog segment dominated in 2021. It is due to the higher efficacy of insulin and minimal adverse effects, such as hypoglycemic attacks and lower weight gain, as compared to conventional therapy
  • The retail pharmacy segment dominated the distribution channel in 2021 due to the presence of retail pharmacy chains and tie-ups of these chains with hospitals
  • North America dominated the market in terms of revenue in 2021, mainly due to the dominance of branded products and the increasing prevalence of diabetes in the region

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market segmentation
    • 1.1.1 Estimates and forecast timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased database
    • 1.3.2 GVR'S internal database
    • 1.3.3 Secondary sources
    • 1.3.4 Primary research
    • 1.3.5 Details of primary research
    • 1.3.6 List of primary sources
  • 1.4 Information or data analysis
    • 1.4.1 Data analysis models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity flow analysis
      • 1.6.1.1 Approach 1: Commodity Flow Approach
      • 1.6.1.2 Approach 2: Country-wise market estimation using the bottom-up approach
  • 1.7 Global Market: CAGR Calculation
  • 1.8 Research Assumptions
  • 1.9 List of Secondary Sources
  • 1.10 List of Abbreviations
  • 1.11 Objectives
    • 1.11.1 Objective 1
    • 1.11.2 Objective 2
    • 1.11.3 Objective 3
    • 1.11.4 Objective 4

Chapter 2 Executive Summary

  • 2.1 Market Summary

Chapter 3 Market Variables, Trends & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent market outlook
  • 3.2 Regulatory framework
  • 3.3 Penetration and Growth Prospect Mapping
  • 3.4 Pipeline Analysis
  • 3.5 Market Dynamics
    • 3.5.1 Market driver analysis
      • 3.5.1.1 Increase in prevalence of diabetes
      • 3.5.1.2 Increase in geriatric and obese population
      • 3.5.1.3 Formulation advancements in insulin delivery systems
    • 3.5.2 Market restraint analysis
      • 3.5.2.1 High cost of insulin
      • 3.5.2.2 Poor reimbursement policies
      • 3.5.2.3 Launch of insulin biosimilars and increasing penetration of glp-1 agonists
  • 3.6 Porter's Five Forces Analysis
  • 3.7 PESTEL Analysis
  • 3.8 COVID-19 Impact

Chapter 4 Global Insulin Market - Segment Analysis, By Product Type, 2018 - 2030 (USD Million)

  • 4.1 Global Insulin Market: Product Type Movement Analysis
  • 4.2 Rapid-Acting Insulin
    • 4.2.1 Rapid-acting insulin market estimates and forecast, 2018 - 2030 (USD Million)
  • 4.3 Long-acting Insulin
    • 4.3.1 Long-acting insulin market estimates and forecast, 2018 - 2030 (USD Million)
  • 4.4 Combination Insulin
    • 4.4.1 Combination insulin market estimates and forecast, 2018 - 2030 (USD Million)
  • 4.5 Biosimilar
    • 4.5.1 Biosimilar market estimates and forecast, 2018 - 2030 (USD Million)
  • 4.6 Others
    • 4.6.1 Other market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 5 Global Insulin Market - Segment Analysis, By Type, 2018 - 2030 (USD Million)

  • 5.1 Global Insulin Market: Type Movement Analysis
  • 5.2 Human Insulin
    • 5.2.1 Human Insulin Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • 5.3 Insulin Analog
    • 5.3.1 Insulin Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6 Global Insulin Market - Segment Analysis, Application, 2018 - 2030 (USD Million)

  • 6.1 Global Insulin Market: Application Movement Analysis
  • 6.2 Type 1 Diabetes Mellitus
    • 6.2.1 Type 1 diabetes mellitus market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.3 Type 2 Diabetes Mellitus
    • 6.3.1 Type 2 diabetes mellitus market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 7 Global Insulin Market - Segment Analysis, By Distribution Channel, 2018 - 2030 (USD Million)

  • 7.1 Global Insulin Market: Distribution Channel Movement Analysis
  • 7.2 Hospital Pharmacy
    • 7.2.1 Hospital pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.3 Retail Pharmacy
    • 7.3.1 Retail pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.4 Others
    • 7.4.1 Other market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 8 Insulin Market: Segment Analysis, by region, 2018 - 2030 (USD Million)

  • 8.1 Insulin Market: Regional Movement Analysis
    • 8.1.1 North America
      • 8.1.1.1 North America market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.1.2 U.S.
      • 8.1.1.2.1 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.1.3 Canada
      • 8.1.1.3.1 Canada market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.1.2 Europe
      • 8.1.2.1 Europe market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.2.2 UK
      • 8.1.2.2.1 UK market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.2.3 Germany
      • 8.1.2.3.1 Germany market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.2.4 France
      • 8.1.2.4.1 France market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.2.5 Spain
      • 8.1.2.5.1 Spain market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.2.6 Italy
      • 8.1.2.6.1 Italy market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.1.3 Asia Pacific
      • 8.1.3.1 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.3.2 Japan
      • 8.1.3.2.1 Japan market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.3.3 China
      • 8.1.3.3.1 China market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.3.4 India
      • 8.1.3.4.1 India market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.3.5 Australia
      • 8.1.3.5.1 Australia market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.3.5 South Korea
      • 8.1.3.5.1 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.1.4 Latin America
      • 8.1.4.1 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.4.2 Brazil
      • 8.1.4.2.1 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.4.3 Mexico
      • 8.1.4.3.1 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.4.4 Argentina
      • 8.1.4.4.1 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.1.5 Middle East & Africa
      • 8.1.5.1 Middle East & Africa market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.5.2 South Africa
      • 8.1.5.2.1 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.5.3 Saudi Arabia
      • 8.1.5.3.1 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.5.5 United Arab Emirates
      • 8.1.5.5.1 United Arab Emirates market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 9 Global Insulin Market: Competitive Analysis

  • 9.1 Recent Developments and Impact Analysis, by Key Market Participants
    • 9.1.1 Synergy analysis: major deals and strategic alliances
      • 9.1.1.1 New Product Launches
      • 9.1.1.2 Mergers and Acquisitions
      • 9.1.1.3 Partnerships & Agreements
  • 9.2 Company Categorization
    • 9.2.1 Innovators
    • 9.2.2 Market Leaders
    • 9.2.3 Emerging Players
    • 9.2.4 Heat Map Analysis
  • 9.3 Company Market Position Analysis
  • 9.4 Vendor Landscape
    • 9.4.1 List of Key Distributors and Channel Partners
    • 9.4.2 List of Potential End-Users
    • 9.4.3 Key Company Market Share Analysis, 2021
  • 9.5 Company Market Share/Ranking, 2021
    • 9.5.1 Company Market Share/Ranking, Rapid-Acting Insulin, 2021
    • 9.5.2 Company Market Share/Ranking, Long-Acting Insulin, 2021
    • 9.5.3 Company Market Share/Ranking, Biosimilars, 2021
    • 9.5.4 Company Market Share/Ranking, Others, 2021
    • 9.5.5 Competitive Dashboard Analysis
  • 9.6 Private Companies
    • 9.6.1 List of Key Emerging Companies
    • 9.6.2 Regional Network Map
  • 9.7 Company Profiles
    • 9.7.1 Eli Lilly and Company
      • 9.7.1.1 Company overview
      • 9.7.1.2 Financial performance
      • 9.7.1.3 Product benchmarking
      • 9.7.1.4 Strategic initiatives
    • 9.7.2 Sanofi
      • 9.7.2.1 Company overview
      • 9.7.2.2 Financial performance
      • 9.7.2.3 Product benchmarking
      • 9.7.2.4 Strategic initiatives
    • 9.7.3 Novo Nordisk A/S
      • 9.7.3.1 Company overview
      • 9.7.3.2 Financial performance
      • 9.7.3.3 Product benchmarking
      • 9.7.3.4 Strategic initiatives
    • 9.7.4 Biocon
      • 9.7.4.1 Company overview
      • 9.7.4.2 Financial performance
      • 9.7.4.3 Product benchmarking
      • 9.7.4.4 Strategic initiatives
    • 9.7.5 Boehringer Ingelheim International GmbH
      • 9.7.5.1 Company overview
      • 9.7.5.2 Financial performance
      • 9.7.5.3 Product benchmarking
      • 9.7.5.4 Strategic initiatives
    • 9.7.6 Tonghua Dongbao Pharmaceutical Co. Ltd.
      • 9.7.6.1 Company overview
      • 9.7.6.2 Product benchmarking
      • 9.7.6.3 Strategic initiatives
    • 9.7.7 Wockhardt
      • 9.7.7.1 Company overview
      • 9.7.7.2 Financial performance
      • 9.7.7.3 Product benchmarking
    • 9.7.8 Julphar
      • 9.7.8.1 Company overview
      • 9.7.8.2 Financial performance
      • 9.7.8.3 Product benchmarking
      • 9.7.8.4 Strategic initiatives
    • 9.7.9 The United Laboratories International Holdings Limited
      • 9.7.9.1 Company overview
      • 9.7.9.2 Financial performance
      • 9.7.9.3 Product benchmarking

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviations
  • Table 3 North America insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 4 North America insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 5 North America insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 6 North America insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 7 U.S. insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 8 U.S. insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 9 U.S. insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 10 U.S. insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 11 Canada insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 12 Canada insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 13 Canada insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 14 Canada insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 15 Europe insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 16 Europe insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 17 Europe insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 18 Europe insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 19 UK insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 20 UK insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 21 UK insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 22 UK insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 23 Germany insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 24 Germany insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 25 Germany insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 26 Germany insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 27 France insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 28 France insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 29 France insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 30 France insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 31 Italy insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 32 Italy insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 33 Italy insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 34 Italy insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 35 Spain insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 36 Spain insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 37 Spain insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 38 Spain insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 39 Asia Pacific insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 43 Japan insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 44 Japan insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 45 Japan insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 46 Japan insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 47 China insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 48 China insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 49 China insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 50 China insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 51 India insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 52 India insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 53 India insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 54 India insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 55 Australia insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 56 Australia insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 57 Australia insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 58 Australia insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 59 South Korea insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 60 South Korea insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 61 South Korea insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 62 South Korea insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 63 Latin America insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 64 Latin America insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 65 Latin America insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 66 Latin America insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 67 Brazil insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 68 Brazil insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 69 Brazil insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 70 Brazil insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 71 Mexico insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 72 Mexico insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 73 Mexico insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 74 Mexico insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 75 Argentina insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 76 Argentina insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 77 Argentina insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 78 Argentina insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 79 MEA insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 80 MEA insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 81 MEA insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 82 MEA insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 8 South Africa insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 82 South Africa insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 83 South Africa insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 84 South Africa insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 85 Saudi Arabia insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 90 UAE insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 91 UAE insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 92 UAE insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 93 UAE insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 94 List of key distributors

List of Figures

  • Fig. 1 Global Insulin market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Commodity flow analysis
  • Fig. 10 Global insulin market snapshot, 2021
  • Fig. 11 Penetration and growth prospect mapping
  • Fig. 12 Global insulin market driver impact
  • Fig. 13 Global diabetes prevalence data and forecast (Numbers in millions)
  • Fig. 14 Global Insulin Market Restraint Impact
  • Fig. 15 Sources of healthcare financing according to country income, 2020 (%)
  • Fig. 16 Porter's five forces analysis
  • Fig. 17 Global insulin market: Product type outlook and key takeaways
  • Fig. 18 Global insulin market: Product type movement analysis
  • Fig. 19 Rapid-acting insulin market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Long-acting insulin market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Combination Insulin market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Biosimilar market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Other market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Global insulin market: type outlook and key takeaways
  • Fig. 25 Global insulin market: Type movement analysis
  • Fig. 26 Human insulin market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Insulin analog market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Global insulin market: Application type outlook and key takeaways
  • Fig. 29 Global insulin market: Application type movement analysis
  • Fig. 30 Type 1 diabetes mellitus market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Type 2 diabetes mellitus market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Global insulin market: Distribution channel outlook and key takeaways
  • Fig. 33 Global insulin market: Distribution channel movement analysis
  • Fig. 34 Hospital pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Retail pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Regional marketplace: Key takeaways
  • Fig. 39 Regional outlook, 2018 & 2030
  • Fig. 40 North America insulin market, 2018 - 2030 (USD Million)
  • Fig. 41 U.S. insulin market, 2018 - 2030 (USD Million)
  • Fig. 42 Canada insulin market, 2018 - 2030 (USD Million)
  • Fig. 43 Europe insulin market, 2018 - 2030 (USD Million)
  • Fig. 44 UK. insulin market, 2018 - 2030 (USD Million)
  • Fig. 45 Germany insulin market, 2018 - 2030 (USD Million)
  • Fig. 46 Italy insulin market, 2018 - 2030 (USD Million)
  • Fig. 47 Spain insulin market, 2018 - 2030 (USD Million)
  • Fig. 48 France insulin market, 2018 - 2030 (USD Million)
  • Fig. 49 Asia Pacific insulin market, 2018 - 2030 (USD Million)
  • Fig. 50 Japan insulin market, 2018 - 2030 (USD Million)
  • Fig. 52 India insulin market, 2018 - 2030 (USD Million)
  • Fig. 53 Australia insulin market, 2018 - 2030 (USD Million)
  • Fig. 54 South Korea insulin market, 2018 - 2030 (USD Million)
  • Fig. 55 Latin America insulin market, 2018 - 2030 (USD Million)
  • Fig. 56 Brazil insulin market, 2018 - 2030 (USD Million)
  • Fig. 57 Mexico insulin market, 2018 - 2030 (USD Million)
  • Fig. 58 Argentina insulin market, 2018 - 2030 (USD Million)
  • Fig. 59 MEA insulin market, 2018 - 2030 (USD Million)
  • Fig. 60 South Africa insulin market, 2018 - 2030 (USD Million)
  • Fig. 61 Saudi Arabia insulin market, 2018 - 2030 (USD Million)
  • Fig. 62 UAE insulin market, 2018 - 2030 (USD Million)
  • Fig. 63 Heat map analysis
  • Fig. 64 Company market position analysis, 2021
  • Fig. 65 Company market position analysis, 2021
  • Fig. 66 Company market share analysis (2021)
  • Fig. 67 Market differentiators